Portal de Periódicos da CAPES

Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies

2021; Cell Press; Volume: 34; Issue: 11 Linguagem: Inglês

10.1016/j.celrep.2021.108852

2639-1856

Nicola Cotugno, Alessandra Ruggiero, Francesco Bonfante, Maria Raffaella Petrara, Sonia Zicari, Giuseppe Rubens Pascucci, Paola Zangari, Maria Antonietta De Ioris, Veronica Santilli, Emma Concetta Manno, Donato Amodio, Alessio Bortolami, Matteo Pagliari, Carlo Concato, Giulia Linardos, Andrea Campana, Daniele Donà, Carlo Giaquinto, Petter Brodin, Paolo Rossi, Anita De Rossi, Paolo Palma, Stefania Bernardi, Lorenza Romani, Paola Pansa, Sara Chiurchiù, Andrea Finocchi, Caterina Cancrini, Laura Lancella, Laura Cursi, Maia De Luca, Renato Cutrera, Libera Sessa, Francesca Rocchi, Chiara Medri, Lorenza Putignani, Francesca Ippolita Calò Carducci, Patrizia D’Argenio, Marta Luisa Ciofi degli Atti, Carmen D’Amore, Livia Piccioni, Martina Di Giuseppe, Alessandro Jenkner, Carmela Giancotta, Andrzej Krzysztofiak,

Long-Term Effects of COVID-19

As the global COVID-19 pandemic progresses, it is paramount to gain knowledge on adaptive immunity to SARS-CoV-2 in children to define immune correlates of protection upon immunization or infection. We analyzed anti-SARS-CoV-2 antibodies and their neutralizing activity (PRNT) in 66 COVID-19-infected children at 7 (±2) days after symptom onset. Individuals with specific humoral responses presented faster virus clearance and lower viral load associated with a reduced in vitro infectivity. We demonstrated that the frequencies of SARS-CoV-2-specific CD4+CD40L+ T cells and Spike-specific B cells were associated with the anti-SARS-CoV-2 antibodies and the magnitude of neutralizing activity. The plasma proteome confirmed the association between cellular and humoral SARS-CoV-2 immunity, and PRNT+ patients show higher viral signal transduction molecules (SLAMF1, CD244, CLEC4G). This work sheds lights on cellular and humoral anti-SARS-CoV-2 responses in children, which may drive future vaccination trial endpoints and quarantine measures policies.